What's in Clare Hayes-Bradley's pipeline?

Clare Hayes-Bradley has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Clare Hayes-Bradley's portfolio?

Top competitors by shared drug class: Diskapi Yildirim Beyazit Education and Research Hospital, Merck Sharp & Dohme LLC, Sir Ganga Ram Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/clare-hayes-bradley.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Clare Hayes-Bradley — Portfolio Competitive Intelligence Brief

Clare Hayes-Bradley pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rocuronium dosing	Rocuronium dosing	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction	Anesthesia

Therapeutic area mix

Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Diskapi Yildirim Beyazit Education and Research Hospital · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Sir Ganga Ram Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Clare Hayes-Bradley:

Cite this brief

Drug Landscape (2026). Clare Hayes-Bradley — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clare-hayes-bradley. Accessed 2026-05-16.